Vendor, South San Francisco, CA
Aligos Therapeutics Inc.
UEI ED19ABDRLV29, CAGE 96ED3
1 award and $2,816,916 obligated between March 29, 2024 and June 18, 2025, 100% under full and open competition, against 7.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)NAICS 541715 | $2,816,916 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93023C00052Definitive Contract, March 29, 2024, Full and Open Competition, 7 offers | National Institutes of Health NiaidNational Institutes of Health | To Conduct Clinical Development of a Compound for the Treatment of Covid-19.NAICS 541715, PSC AN12 | $2,816,916 |
- Places of performance
- California
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 4 across 1 awards